Synthetic Biologics, Inc.(NYSE Amex Equities : SYN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||-0.58%||450.57||2.7%||$522.91m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.20%||212.55||1.9%||$515.41m|
|GILD||Gilead Sciences, Inc.||-2.21%||61.40||1.0%||$485.52m|
|BNGO||BioNano Genomics, Inc.||-2.89%||9.73||0.0%||$374.38m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.59%||152.75||2.0%||$371.25m|
|CRSP||CRISPR Therapeutics AG||-1.25%||125.69||0.6%||$292.02m|
|EXAS||EXACT Sciences Corp.||3.67%||136.12||18.4%||$252.07m|
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.